WO2005076007A3 - Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) - Google Patents
Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) Download PDFInfo
- Publication number
- WO2005076007A3 WO2005076007A3 PCT/EP2005/000632 EP2005000632W WO2005076007A3 WO 2005076007 A3 WO2005076007 A3 WO 2005076007A3 EP 2005000632 W EP2005000632 W EP 2005000632W WO 2005076007 A3 WO2005076007 A3 WO 2005076007A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- therapeutics
- diagnostics
- protein
- diseases associated
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 abstract 1
- 101710192338 P2Y purinoceptor 12 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000043971 human P2RY12 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne le P2Y12 humain associé aux maladies cardio-vasculaires, aux maladies endocrinologiques, aux maladies métaboliques, aux maladies gastroentérologiques, au cancer, aux inflammations, aux maladies hématologiques, aux maladies respiratoires, aux maladies neurologiques et aux maladies urologiques. L'invention concerne également des dosages permettant d'identifier des composés utilisés pour traiter ou prévenir les maladies cardio-vasculaires, les maladies endocrinologiques, les maladies métaboliques, les maladies gastroentérologiques, le cancer, les inflammations, les maladies hématologiques, les maladies respiratoires, les maladies neurologiques et les maladies urologiques. L'invention concerne enfin des composés qui se lient à P2Y12 et/ou activent or inhibent son activité ainsi que des compositions pharmaceutiques comprenant ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04002290.7 | 2004-02-03 | ||
| EP04002290 | 2004-02-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005076007A2 WO2005076007A2 (fr) | 2005-08-18 |
| WO2005076007A3 true WO2005076007A3 (fr) | 2006-01-26 |
Family
ID=34833561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/000632 WO2005076007A2 (fr) | 2004-02-03 | 2005-01-22 | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005076007A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299097B2 (en) | 2008-09-12 | 2012-10-30 | The Brigham And Women's Hospital, Inc. | Methods for treating inflammatory disorders |
| NZ705731A (en) * | 2010-10-18 | 2017-02-24 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| AU2015227476B2 (en) * | 2010-10-18 | 2017-03-23 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| US9539246B2 (en) | 2011-08-30 | 2017-01-10 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010046497A1 (en) * | 2000-04-21 | 2001-11-29 | Zhang Fang Liang | G-protein coupled receptor and methods |
| US20030124626A1 (en) * | 2000-11-01 | 2003-07-03 | Jun Takasaki | Method of screening antiplatelet |
| WO2004065576A2 (fr) * | 2003-01-15 | 2004-08-05 | Millennium Pharmaceuticals, Inc. | Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603, |
-
2005
- 2005-01-22 WO PCT/EP2005/000632 patent/WO2005076007A2/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010046497A1 (en) * | 2000-04-21 | 2001-11-29 | Zhang Fang Liang | G-protein coupled receptor and methods |
| US20030124626A1 (en) * | 2000-11-01 | 2003-07-03 | Jun Takasaki | Method of screening antiplatelet |
| WO2004065576A2 (fr) * | 2003-01-15 | 2004-08-05 | Millennium Pharmaceuticals, Inc. | Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603, |
Non-Patent Citations (3)
| Title |
|---|
| HOLLOPETER GUNTHER ET AL: "Identification of the platelet ADP receptor targeted by antithrombotic drugs", NATURE (LONDON), vol. 409, no. 6817, 11 January 2001 (2001-01-11), pages 202 - 207, XP002333079, ISSN: 0028-0836 * |
| KUNAPULI SATYA P ET AL: "ADP receptors-targets for developing antithrombotic agents.", CURRENT PHARMACEUTICAL DESIGN, vol. 9, no. 28, 2003, pages 2303 - 2316, XP008049019, ISSN: 1381-6128 * |
| TAKASAKI JUN ET AL: "Molecular cloning of the platelet P2TAC ADP receptor: Pharmacological comparison with another ADP receptor, the P2Y1 receptor", MOLECULAR PHARMACOLOGY, vol. 60, no. 3, September 2001 (2001-09-01), pages 432 - 439, XP002333080, ISSN: 0026-895X * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005076007A2 (fr) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr) | |
| WO2005093092A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44) | |
| WO2006005469A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr) | |
| WO2005076007A3 (fr) | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) | |
| WO2005103684A3 (fr) | Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c | |
| WO2006021343A3 (fr) | Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a) | |
| WO2005031345A3 (fr) | Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2) | |
| WO2005073729A3 (fr) | Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) | |
| WO2005093091A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26) | |
| WO2005101001A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c) | |
| WO2005113786A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) | |
| WO2005113788A3 (fr) | Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6) | |
| WO2005119263A3 (fr) | Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92) | |
| WO2005075983A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3) | |
| WO2006005470A3 (fr) | Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge) | |
| WO2005040791A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) | |
| WO2005114209A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 2 specifique du recepteur couple a une proteine g (grk2) | |
| WO2005106486A3 (fr) | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) | |
| WO2005114210A8 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3) | |
| WO2006040047A3 (fr) | Diagnostics et therapeutiques pour des maladies associees a la kinase citron agissant sur rho/rac | |
| WO2005101011A3 (fr) | Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra) | |
| WO2005108998A3 (fr) | Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3) | |
| WO2006013013A3 (fr) | Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb) | |
| WO2005101006A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur beta du retinoide x (rxrb) | |
| WO2005075990A3 (fr) | Diagnostics et therapeutiques pour maladies associees au recepteur nucleaire humain nr4a2 (nr4a2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |